Alto Neuroscience, Inc. (ANRO) Stock

Alto Neuroscience, Inc. (ANRO) is a Healthcare stock trading at $22.68 (as of 2026-06-18), with a market capitalization of $661.52M and a trailing P/E of -8.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing psychiatric therapeutics. Its programs include small-molecule candidates and combination approaches for conditions such as major depressive disorder, post-traumatic stress disorder, cognitive impairment associated with schizophrenia, and related symptom profiles, along with an AI-enabled biomarker platform to help identify patients likely to respond.

Valuation — source: SEC EDGAR (first-party)
Price	$22.68
Market Cap	$661.52M
P/E Ratio	-8.8
EV / EBITDA	-6.5
Price / Book	3.10
Price / Sales	118.90
DCF Value (model)	$-22.59
DCF Upside vs Price	-199.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$6.60M
Net Margin	-957.7%
Return on Equity	-30.5%
Debt / Equity	0.07
Current Ratio	20.52
Revenue Growth (YoY)	-25.4%
EPS Growth (YoY)	-12.4%
FCF Growth (YoY)	4.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	11.36 (safe)

Valuation vs Sector & Industry
Stock P/E	-8.8
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-142.3%
vs Industry	-151.9%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Alpha Wave Global, LP ($83.35M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Amit Etkin
Employees	76
Country	US
IPO Date	2024-02-02

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.